GER
MCID: GST092
MIFTS: 66

Gastroesophageal Reflux (GER)

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Gastroesophageal Reflux

MalaCards integrated aliases for Gastroesophageal Reflux:

Name: Gastroesophageal Reflux 58 12 77 30 13 6 45 15
Gastroesophageal Reflux Disease 58 12 38 56 15 17 74
Gerd 58 12 44
Gerd - Gastro-Esophageal Reflux Disease 12
Gastroesophageal Reflux Disease; Gerd 58
Gastroesophageal Reflux, Pediatric 58
Gastro-Esophageal Reflux 12
Gastresophageal Reflux 12
Acid Reflux 12
Ger 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
gastroesophageal reflux:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:8534
OMIM 58 109350
KEGG 38 H01602
ICD9CM 36 530.81
MeSH 45 D005764
NCIt 51 C26781
SNOMED-CT 69 54856001
ICD10 34 K21 K21.9
MedGen 43 C0017168
UMLS 74 C0017168

Summaries for Gastroesophageal Reflux

MedlinePlus : 44 Your esophagus is the tube that carries food from your mouth to your stomach. Gastroesophageal reflux disease (GERD) happens when a muscle at the end of your esophagus does not close properly. This allows stomach contents to leak back, or reflux, into the esophagus and irritate it. You may feel a burning in the chest or throat called heartburn. Sometimes, you can taste stomach fluid in the back of the mouth. If you have these symptoms more than twice a week, you may have GERD. You can also have GERD without having heartburn. Your symptoms could include a dry cough, asthma symptoms, or trouble swallowing. Anyone, including infants and children, can have GERD. If not treated, it can lead to more serious health problems. In some cases, you might need medicines or surgery. However, many people can improve their symptoms by Avoiding alcohol and spicy, fatty or acidic foods that trigger heartburn Eating smaller meals Not eating close to bedtime Losing weight if needed Wearing loose-fitting clothes NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Gastroesophageal Reflux, also known as gastroesophageal reflux disease, is related to peptic esophagitis and barrett esophagus, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastroesophageal Reflux is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Peptide ligand-binding receptors and Toll Comparative Pathway. The drugs Calcium polycarbophil and Rabeprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and kidney, and related phenotypes are gastroesophageal reflux and esophagitis

OMIM : 58 Gastroesophageal reflux (GER) is characterized by the retrograde movement of stomach contents into the esophagus. In its most severe form, GER results in extensive tissue damage caused by acid reflux. In adolescents and adults, and even infrequently in children, chronic GER is associated with the risk of developing Barrett metaplasia (614266), a premalignant lesion of the esophageal mucosa (Hu et al., 2000). In turn, Barrett metaplasia is correlated with the development of adenocarcinoma of the esophagus (see 614266), estimated as the fifth most prevalent neoplasia in the Western world (Lagergren et al., 1999). (109350)

Wikipedia : 77 Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition in which... more...

Related Diseases for Gastroesophageal Reflux

Diseases related to Gastroesophageal Reflux via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 32.7 CXCL8 CYP2C19 HRH2 IL1B
2 barrett esophagus 32.7 CDX2 GAST PTGS2 TP53
3 gastroparesis 32.5 CCK GAST GHRL MLN
4 helicobacter pylori infection 31.4 CXCL8 CYP2C19 GAST IL1B
5 dyspepsia 31.4 PTGS2 PTGS1 HRH2 GHRL CYP2C19 CXCL8
6 sleep apnea 31.2 CXCL8 GHRL IL1B
7 irritable bowel syndrome 31.2 CCK MLN PYY
8 esophagitis 30.8 TP53 PTGS2 IL1B HRH2 CYP2C19 CXCL8
9 duodenal ulcer 30.5 CCK CXCL8 CYP2C19 GAST HRH2 IL1B
10 bile reflux 30.4 CCK CDX2 PTGS2
11 morbid obesity 30.3 CCK GCG GHRL PYY
12 recurrent respiratory papillomatosis 30.3 PTGS2 TP53
13 zollinger-ellison syndrome 30.2 GAST HRH2 NTS
14 duodenogastric reflux 30.2 CCK GAST MLN NTS PYY
15 constipation 30.2 CCK CHAT GAST MLN NTS PYY
16 pylorospasm 30.1 GAST GHRL MLN
17 pharyngitis 30.0 CXCL8 IL1B PTGS2
18 bulimia nervosa 30.0 CCK GHRL PYY
19 atrophic gastritis 29.9 CDX2 CXCL8 GAST GHRL IL1B TP53
20 gastritis 29.8 PTGS2 IL1B HRH2 GHRL GAST CXCL8
21 peptic ulcer disease 29.8 PTGS2 IL1B HRH2 GHRL GAST CYP2C19
22 dumping syndrome 29.8 GCG NTS PYY
23 esophagus adenocarcinoma 29.8 CDX2 PTGS2 TP53
24 stomach disease 29.7 TP53 PTGS2 PTGS1 MLN IL1B HRH2
25 active peptic ulcer disease 29.6 HRH2 PTGS1 PTGS2
26 gastric ulcer 29.5 PTGS2 PTGS1 IL1B HRH2 GAST CYP2C19
27 anorexia nervosa 29.4 CCK GHRL PYY
28 rheumatic disease 29.2 IL1B PTGS1 PTGS2
29 myocardial infarction 28.9 CYP2C19 GHRL IL1B PTGS1 PTGS2
30 gastrointestinal system disease 28.5 TP53 PYY PTGS2 MLN IL1B GHRL
31 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 12.7
32 spastic paraplegia 9a, autosomal dominant 11.7
33 hernia, hiatus 11.7
34 spastic paraplegia 9 11.7
35 type ii mixed cryoglobulinemia 11.6
36 chronic laryngitis 11.5
37 sandifer syndrome 11.5
38 down syndrome 11.5
39 chronic hiccups 11.5
40 jackhammer esophagus 11.5
41 neuropathy, hereditary sensory and autonomic, type iia 11.3
42 sudden infant death with dysgenesis of the testes syndrome 11.3
43 mental retardation, autosomal dominant 47 11.3
44 dihydropyrimidinase deficiency 11.2
45 lubs x-linked mental retardation syndrome 11.2
46 encephalopathy, neonatal severe, due to mecp2 mutations 11.2
47 mental retardation, x-linked 98 11.2
48 phelan-mcdermid syndrome 11.2
49 spastic paraplegia 49, autosomal recessive 11.2
50 combined oxidative phosphorylation deficiency 19 11.2

Comorbidity relations with Gastroesophageal Reflux via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Deficiency Anemia Dyskinesia of Esophagus
Esophagitis Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Osteoporosis Peptic Esophagitis

Graphical network of the top 20 diseases related to Gastroesophageal Reflux:



Diseases related to Gastroesophageal Reflux

Symptoms & Phenotypes for Gastroesophageal Reflux

Human phenotypes related to Gastroesophageal Reflux:

33
# Description HPO Frequency HPO Source Accession
1 gastroesophageal reflux 33 HP:0002020
2 esophagitis 33 HP:0100633
3 barrett esophagus 33 HP:0100580

Symptoms via clinical synopsis from OMIM:

58
G I:
gastroesophageal reflux
chronic ulcerating esophagitis

Lab:
columnar epithelium-lined distal esophagus

Oncology:
adenocarcinoma of the esophagus risk about 10%

Clinical features from OMIM:

109350

UMLS symptoms related to Gastroesophageal Reflux:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastroesophageal Reflux:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.86 CDX2 CHAT GAST GHRL HRH2 PTGS1
2 endocrine/exocrine gland MP:0005379 9.81 CCK CDX2 F2RL1 GAST GHRL HRH2
3 homeostasis/metabolism MP:0005376 9.77 CCK CDX2 CHAT F2RL1 GAST GHRL
4 neoplasm MP:0002006 9.17 CDX2 F2RL1 GAST IL1B PTGS1 PTGS2

Drugs & Therapeutics for Gastroesophageal Reflux

Drugs for Gastroesophageal Reflux (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 637)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium polycarbophil Approved Phase 4 126040-58-2
2
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 117976-89-3 5029
3
Trimebutine Approved Phase 4 39133-31-8
4
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3 3883
5
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 138530-94-6, 103577-45-3 9578005
6
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 73590-58-6 4594
7
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
8
mometasone furoate Approved, Investigational, Vet_approved Phase 4,Phase 2 83919-23-7
9
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57808-66-9 3151
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
11
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
12
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
13
Fluticasone Approved, Experimental Phase 4,Phase 2,Phase 3,Not Applicable 90566-53-3 62924
14
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
15
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
16
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
17
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
18
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
19
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 58-05-9 6006 143
20
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
22
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1134-47-0 2284
23
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2 57-27-2 5288826
24
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
25
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
26
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1309-42-8
27
Metoclopramide Approved, Investigational Phase 4,Phase 3,Not Applicable 364-62-5 4168
28
Ranitidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 66357-59-3, 66357-35-5 3001055
29
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
30
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
31
Prucalopride Approved Phase 4,Not Applicable 179474-81-8
32
Citalopram Approved Phase 4 59729-33-8 2771
33
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3 67-20-9 5353830
34
Polidocanol Approved Phase 4,Phase 3,Phase 2,Phase 1 9002-92-0
35
Nortriptyline Approved Phase 4,Phase 3,Phase 2 72-69-5 4543
36
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
37
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
38
Ziprasidone Approved Phase 4 146939-27-7 60854
39
Lithium carbonate Approved Phase 4 554-13-2
40
Clozapine Approved Phase 4 5786-21-0 2818
41
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
42
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
43
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
44
Aluminum hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 21645-51-2
45
Magnesium trisilicate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14987-04-3
46
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
47
Famotidine Approved Phase 4,Phase 2,Phase 3,Not Applicable 76824-35-6 3325
48
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
49
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
50
Iodine Approved, Investigational Phase 4 7553-56-2 807

Interventional clinical trials:

(show top 50) (show all 1406)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Unknown status NCT01882088 Phase 4 Mucofalk
2 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
3 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
4 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
5 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
6 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
7 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
8 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
9 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
10 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
11 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
12 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
13 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
14 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
15 PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena Unknown status NCT00526006 Phase 4 esomeprazole
16 Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery Unknown status NCT02050477 Phase 4
17 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
18 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
19 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
20 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
21 Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice Unknown status NCT00363701 Phase 4 esomeprazole
22 The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease Completed NCT02505945 Phase 4 Omeprazole
23 Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication Not yet recruiting NCT02934152 Phase 4 H pylori eradication
24 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
25 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Recruiting NCT03467438 Phase 4 Zinc-l-carnosine
26 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
27 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
28 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
29 Methoclopramide for Gastroesophageal Reflux in Premature Infants Recruiting NCT02907632 Phase 4 Metoclopramide;Placebo
30 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole
31 Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis Completed NCT03086070 Phase 4 Omeprazole 20mg;Placebo oral capsule
32 Comparison of Voice Therapy and Antireflex Therapy in LPR Withdrawn NCT02530879 Phase 4 Omeprazole, Lansoprazole, Esomeprazole, Rantidine
33 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
34 The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux Withdrawn NCT02123498 Phase 4 Omeprazole;Ranitidine;Pantoprazole
35 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
36 Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing Terminated NCT00537732 Phase 4 omeprazole;omeprazole
37 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
38 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4 Prevacid
39 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
40 Esomeprazole and Gastric Emptying of Beer Completed NCT00472550 Phase 4 esomeprazole 20 mg
41 Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux Terminated NCT00369265 Phase 4 Lansoprazole
42 A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease Terminated NCT01281553 Phase 4 Placebo;Cisapride
43 Prucalopride Treatment for Refractory Gastro-esophageal Reflux Disease Recruiting NCT03676374 Phase 4 Prucalopride;Placebo Oral Tablet
44 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4 Aflurax;esomeprazole
45 Effect of Citalopram on Reflux Episodes in Healthy Volunteers Completed NCT03746691 Phase 4 Citalopram HCl;Placebos
46 Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Completed NCT00287391 Phase 4 Rabeprazole
47 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
48 A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) Completed NCT00216489 Phase 4 rabeprazole sodium
49 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
50 Citalopram for Reflux Hypersensitivity and Functional Heartburn Recruiting NCT03499171 Phase 4 Citalopram 20mg;Placebo Oral Tablet

Search NIH Clinical Center for Gastroesophageal Reflux

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: gastroesophageal reflux

Genetic Tests for Gastroesophageal Reflux

Genetic tests related to Gastroesophageal Reflux:

# Genetic test Affiliating Genes
1 Gastroesophageal Reflux 30

Anatomical Context for Gastroesophageal Reflux

MalaCards organs/tissues related to Gastroesophageal Reflux:

42
Testes, Lung, Kidney, Liver, Bone, Lymph Node, Tongue

Publications for Gastroesophageal Reflux

Articles related to Gastroesophageal Reflux:

(show top 50) (show all 4393)
# Title Authors Year
1
Plasma levels of TNF-α, IL-6, IFN-γ, IL-12, IL-17, IL-22, and IL-23 in achalasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (GERD). ( 30744559 )
2019
2
Association of atrial fibrillation and gastroesophageal reflux disease: Natural and therapeutic linkage of the two common diseases. ( 30805043 )
2019
3
The type of dyspepsia is important in the context of patients with irritable bowel syndrome and gastroesophageal reflux disease. ( 30670341 )
2019
4
Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study. ( 30673836 )
2019
5
Reply to: "The type of dyspepsia is important in the context of patients with irritable bowel syndrome and gastroesophageal reflux disease". ( 30704814 )
2019
6
Correction to: Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study. ( 30859319 )
2019
7
Impact of Chronic Statins Use on the Development of Esophagitis in Patients with Gastroesophageal Reflux Disease. ( 30854351 )
2019
8
Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study. ( 30638085 )
2019
9
IgG4 is Elevated in Eosinophilic Esophagitis but Not in Gastroesophageal Reflux Disease Patients. ( 30614939 )
2019
10
Comparison of double-flap and OrVil techniques of laparoscopy-assisted proximal gastrectomy in preventing gastroesophageal reflux: a retrospective cohort study. ( 30612151 )
2019
11
Acid exposure in patients with gastroesophageal reflux disease is associated with esophageal dysmotility. ( 30629802 )
2019
12
Are Diet and Micronutrients Effective in Treating Gastroesophageal Reflux Disease Especially in Women? ( 30646473 )
2019
13
Validation of the Korean Version of the Gastroesophageal Reflux Disease Questionnaire for the Diagnosis of Gastroesophageal Reflux Disease. ( 30646480 )
2019
14
Prevalence of Gastroesophageal Reflux Disease Symptoms in Infants and Children: A Systematic Review. ( 30676525 )
2019
15
Detection of laryngeal carcinoma in the U.S. elderly population with gastroesophageal reflux disease. ( 30681216 )
2019
16
Association between tea consumption and gastroesophageal reflux disease: A meta-analysis. ( 30681584 )
2019
17
Melatonin for the treatment of gastroesophageal reflux disease; protocol for a systematic review and meta-analysis. ( 30681611 )
2019
18
Gastroesophageal reflux disease in a patient with BMI 30kg/m2 and previous endoscopic vertical gastroplasty: Indication for a one anastomosis gastric bypass. ( 30683273 )
2019
19
Do patients with gastroesophageal reflux disease and somatoform tendencies benefit from antireflux surgery? ( 30686906 )
2019
20
Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment. ( 30688703 )
2019
21
Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment. ( 30688704 )
2019
22
The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality. ( 30715227 )
2019
23
What is this image? 2019: Image 5 result : Gastroesophageal reflux: An unexpected cause of chest pain identified by review of planar images and coregistered SPECT-CT images. ( 30719654 )
2019
24
Laparoscopic total duodenal diversion in the treatment of complex gastroesophageal reflux disease. ( 30772085 )
2019
25
Prevalence and factors associated with gastroesophageal reflux disease in southern India: A community-based study. ( 30790137 )
2019
26
Gastroesophageal reflux disease (GERD). ( 30795847 )
2019
27
The effectiveness of mindfulness meditation in relief of symptoms of depression and quality of life in patients with gastroesophageal reflux disease. ( 30864012 )
2019
28
Unique Clinical Features of Los Angeles Grade D Esophagitis Suggest That Factors Other Than Gastroesophageal Reflux Contribute to its Pathogenesis. ( 28644313 )
2019
29
Proteomics of acquired pellicle in gastroesophageal reflux disease patients with or without erosive tooth wear. ( 30579861 )
2019
30
Upper Esophageal Sphincter Dysfunction in Gastroesophageal Reflux Disease. ( 30798361 )
2019
31
Management of gastroesophageal reflux disease. ( 30798984 )
2019
32
Natural history, pathophysiology and evaluation of gastroesophageal reflux disease. ( 30803725 )
2019
33
Real-time MRI for the dynamic assessment of fundoplication failure in patients with gastroesophageal reflux disease. ( 30805702 )
2019
34
Minor psychiatric disorders and objective diagnosis of gastroesophageal reflux disease. ( 30815740 )
2019
35
Correction to: Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan. ( 30815827 )
2019
36
Gastroesophageal Reflux Disease in the Neonatal Intensive Care Unit Infant: Who Needs to Be Treated and What Approach Is Beneficial? ( 30819348 )
2019
37
Gastroesophageal Reflux Induces Protein Adducts in the Esophagus. ( 30827415 )
2019
38
Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus. ( 30831146 )
2019
39
Prenatal use of medications for gastroesophageal reflux disease and early childhood fracture risk. ( 30834583 )
2019
40
Similar Effectiveness of Total and 270° Posterior Fundoplication for the Treatment of Gastroesophageal Reflux Disease. ( 30840051 )
2019
41
Comparison of Laparoscopic 270° Posterior Partial Fundoplication vs Total Fundoplication for the Treatment of Gastroesophageal Reflux Disease: A Randomized Clinical Trial. ( 30840057 )
2019
42
A population-based study on prevalence and risk factors of gastroesophageal reflux disease in the Tibet Autonomous Region, China. ( 30842901 )
2019
43
Clinical and psychological characteristics in GERD patients overlapping with laryngopharyngeal reflux symptoms. ( 30851003 )
2019
44
Association between tea consumption and gastroesophageal reflux disease: A meta-analysis: Erratum. ( 30855514 )
2019
45
Relationship Between Torticollis and Gastroesophageal Reflux Disorder in Infants. ( 30865145 )
2019
46
Radiofrequency ablation is safe and effective in the treatment of Chinese patients with gastroesophageal reflux disease: A single-center prospective study. ( 30873743 )
2019
47
Management of Pediatric Gastroesophageal Reflux Disease. ( 30882857 )
2019
48
Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. ( 30883868 )
2019
49
Increased risk of larynx cancer in patients with gastroesophageal reflux disease from a national sample cohort. ( 30884136 )
2019
50
Diagnosis and Management of Gastroesophageal Reflux Disease in Infants and Children: from Guidelines to Clinical Practice. ( 30899687 )
2019

Variations for Gastroesophageal Reflux

ClinVar genetic disease variations for Gastroesophageal Reflux:

6 (show all 30)
# Gene Variation Type Significance SNP ID Assembly Location
1 FAM120AOS NM_198841.3(FAM120AOS): c.743C> T (p.Thr248Ile) single nucleotide variant Likely pathogenic rs140119177 GRCh38 Chromosome 9, 93447639: 93447639
2 FAM120AOS NM_198841.3(FAM120AOS): c.743C> T (p.Thr248Ile) single nucleotide variant Likely pathogenic rs140119177 GRCh37 Chromosome 9, 96209921: 96209921
3 RPS6KA3 NM_004586.2(RPS6KA3): c.533C> G (p.Ala178Gly) single nucleotide variant Likely pathogenic rs1057518914 GRCh37 Chromosome X, 20211665: 20211665
4 RPS6KA3 NM_004586.2(RPS6KA3): c.533C> G (p.Ala178Gly) single nucleotide variant Likely pathogenic rs1057518914 GRCh38 Chromosome X, 20193547: 20193547
5 COL5A1 NM_000093.4(COL5A1): c.608G> T (p.Gly203Val) single nucleotide variant Likely pathogenic rs1554781700 GRCh37 Chromosome 9, 137593133: 137593133
6 COL5A1 NM_000093.4(COL5A1): c.608G> T (p.Gly203Val) single nucleotide variant Likely pathogenic rs1554781700 GRCh38 Chromosome 9, 134701287: 134701287
7 CHAT NM_020549.4(CHAT): c.1061C> T (p.Thr354Met) single nucleotide variant Conflicting interpretations of pathogenicity rs769234940 GRCh37 Chromosome 10, 50835781: 50835781
8 CHAT NM_020549.4(CHAT): c.1061C> T (p.Thr354Met) single nucleotide variant Conflicting interpretations of pathogenicity rs769234940 GRCh38 Chromosome 10, 49627735: 49627735
9 CHAT NM_020549.4(CHAT): c.2081C> G (p.Ser694Cys) single nucleotide variant Pathogenic rs201439531 GRCh37 Chromosome 10, 50872926: 50872926
10 CHAT NM_020549.4(CHAT): c.2081C> G (p.Ser694Cys) single nucleotide variant Pathogenic rs201439531 GRCh38 Chromosome 10, 49664880: 49664880
11 ABCC8 NM_000352.4(ABCC8): c.1793G> A (p.Arg598Gln) single nucleotide variant Likely pathogenic rs1344172059 GRCh38 Chromosome 11, 17430838: 17430838
12 ABCC8 NM_000352.4(ABCC8): c.1793G> A (p.Arg598Gln) single nucleotide variant Likely pathogenic rs1344172059 GRCh37 Chromosome 11, 17452385: 17452385
13 ZNF469 NM_001127464.2(ZNF469): c.2569A> G (p.Asn857Asp) single nucleotide variant Uncertain significance rs1555518955 GRCh37 Chromosome 16, 88496447: 88496447
14 ZNF469 NM_001127464.2(ZNF469): c.2569A> G (p.Asn857Asp) single nucleotide variant Uncertain significance rs1555518955 GRCh38 Chromosome 16, 88430039: 88430039
15 ZNF469 NM_001127464.2(ZNF469): c.9448G> A (p.Gly3150Ser) single nucleotide variant Uncertain significance rs887755283 GRCh38 Chromosome 16, 88437002: 88437002
16 ZNF469 NM_001127464.2(ZNF469): c.9448G> A (p.Gly3150Ser) single nucleotide variant Uncertain significance rs887755283 GRCh37 Chromosome 16, 88503410: 88503410
17 ACTL6A NM_004301.4(ACTL6A): c.1129C> T (p.Arg377Trp) single nucleotide variant Likely pathogenic rs868064163 GRCh38 Chromosome 3, 179586552: 179586552
18 SYNE2 NM_182914.2(SYNE2): c.19624G> T (p.Gly6542Trp) single nucleotide variant Uncertain significance GRCh37 Chromosome 14, 64685197: 64685197
19 SYNE2 NM_182914.2(SYNE2): c.19624G> T (p.Gly6542Trp) single nucleotide variant Uncertain significance GRCh38 Chromosome 14, 64218479: 64218479
20 RYR1 NM_000540.2(RYR1): c.10097G> T (p.Arg3366Leu) single nucleotide variant Uncertain significance GRCh37 Chromosome 19, 39009932: 39009932
21 RYR1 NM_000540.2(RYR1): c.10097G> T (p.Arg3366Leu) single nucleotide variant Uncertain significance GRCh38 Chromosome 19, 38519292: 38519292
22 ACTL6A NM_004301.4(ACTL6A): c.1129C> T (p.Arg377Trp) single nucleotide variant Likely pathogenic rs868064163 GRCh37 Chromosome 3, 179304340: 179304340
23 ZNF469 NM_001127464.2(ZNF469): c.470G> A (p.Gly157Glu) single nucleotide variant Uncertain significance rs781096189 GRCh37 Chromosome 16, 88494348: 88494348
24 ZNF469 NM_001127464.2(ZNF469): c.470G> A (p.Gly157Glu) single nucleotide variant Uncertain significance rs781096189 GRCh38 Chromosome 16, 88427940: 88427940
25 Translocation Pathogenic
26 46;XX;t(4;14)(p15.2;q13)dn Translocation Likely pathogenic
27 46;XY;t(3;5)(q23;q13)dn Translocation Likely pathogenic
28 46;XY;t(9;16)(p24;q22)dn Translocation Pathogenic
29 ABCC8 NM_000352.4(ABCC8): c.3517G> A (p.Val1173Met) single nucleotide variant Likely pathogenic rs141322087 GRCh38 Chromosome 11, 17404552: 17404552
30 ABCC8 NM_000352.4(ABCC8): c.3517G> A (p.Val1173Met) single nucleotide variant Likely pathogenic rs141322087 GRCh37 Chromosome 11, 17426099: 17426099

Cosmic variations for Gastroesophageal Reflux:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM12475 CDKN2A upper aerodigestive tract,mouth,other,premalignant c.238C>T p.R80* 9:21971121-21971121 0
2 COSM12512 CDKN2A upper aerodigestive tract,mouth,other,premalignant c.262G>T p.E88* 9:21971097-21971097 0

Expression for Gastroesophageal Reflux

Search GEO for disease gene expression data for Gastroesophageal Reflux.

Pathways for Gastroesophageal Reflux

Pathways related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 CCK CXCL8 F2RL1 GCG GHRL HRH2
2
Show member pathways
12.11 CXCL8 IL1B PTGS2 TP53
3
Show member pathways
12.11 IL1B PTGS1 PTGS2 TP53
4 11.75 CXCL8 IL1B TP53
5 11.68 CXCL8 IL1B PTGS2
6 11.54 CXCL8 IL1B PTGS2 TP53
7 11.52 CCL26 IL1B PTGS2
8
Show member pathways
11.43 CXCL8 IL1B PTGS2
9 11.31 CXCL8 IL1B PTGS2 TP53
10 11.29 CXCL8 PTGS2 TP53
11 11.23 CXCL8 IL1B PTGS2
12 10.71 PTGS1 PTGS2
13 10.28 CCK GAST
14 10.08 CXCL8 PTGS1 PTGS2
15 10.02 GAST HRH2

GO Terms for Gastroesophageal Reflux

Cellular components related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CCK CCL26 CXCL8 GAST GCG GHRL
2 organelle membrane GO:0031090 9.33 CYP2C19 PTGS1 PTGS2
3 extracellular region GO:0005576 9.32 CCK CCL26 CXCL8 GAST GCG GHRL

Biological processes related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.97 CCK CCL26 CXCL8 F2RL1 GAST GCG
2 cytokine-mediated signaling pathway GO:0019221 9.83 CXCL8 IL1B PTGS2 TP53
3 G protein-coupled receptor signaling pathway GO:0007186 9.7 CCK CCL26 CXCL8 F2RL1 GAST GCG
4 neutrophil chemotaxis GO:0030593 9.65 CCL26 CXCL8 IL1B
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.63 CCL26 F2RL1 GCG
6 inflammatory response GO:0006954 9.63 CCL26 CXCL8 F2RL1 IL1B PTGS1 PTGS2
7 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.56 F2RL1 IL1B
8 positive regulation of protein oligomerization GO:0032461 9.55 CCK TP53
9 prostaglandin biosynthetic process GO:0001516 9.54 PTGS1 PTGS2
10 positive regulation of chemotaxis GO:0050921 9.51 CCL26 F2RL1
11 cyclooxygenase pathway GO:0019371 9.43 PTGS1 PTGS2
12 memory GO:0007613 9.43 CCK HRH2 PTGS2
13 neutrophil activation GO:0042119 9.4 CXCL8 F2RL1
14 positive regulation of fever generation GO:0031622 9.37 IL1B PTGS2
15 regulation of signaling receptor activity GO:0010469 9.32 CCK CCL26 CXCL8 GAST GCG GHRL
16 ovulation GO:0030728 9.19 PTGS2

Molecular functions related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.33 CCK NTS PYY
2 hormone activity GO:0005179 9.1 CCK GAST GCG GHRL MLN PYY
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2

Sources for Gastroesophageal Reflux

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....